HW221043 / Humanwell Healthcare - LARVOL DELTA

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=99 | Not yet recruiting | Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

New P1 trial • Oncology • Solid Tumor

Discovery of HW221043, a potent and orally bioavailable KIF18A inhibitor for treating chromosomal instability in cancer (AACR 2025) - "These findings provide pharmacological proof-of-concept for the synthetic lethal effect of HW221043 and support KIF18A inhibition as a novel therapeutic strategy in oncology. HW221043 is currently in the Investigational New Drug (IND) enabling stage of development."

Oncology • KIF18A